SCHEMBL2589045

SCHEMBL2589045

CCOC(=O)Cc1ncccc1C(=O)O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.61
MAPK1 P28482 1/20 0.61
SMN1; SMN2 Q16637 6/20 0.48
L3MBTL1 Q9Y468 3/20 0.48
KDM4E B2RXH2 2/20 0.46
TDP1 Q9NUW8 1/20 0.46
HTT P42858 2/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
ALDH1A1 P00352 2/20 0.45
CYP3A4 P08684 1/20 0.45
ALOX15 P16050 1/20 0.45
TSHR P16473 1/20 0.45
BLM P54132 1/20 0.45
AGER Q15109 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
TP53 P04637 1/20 0.45
LMNA P02545 2/20 0.44
MYC P01106 1/20 0.44
NAPRT Q6XQN6 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30177224 1.00 MAPT (0.61) MAPTMAPK1SMN1; SMN2L3MBTL1KDM4E
SCHEMBL10515633 0.88 MAPT (0.60) MAPTMAPK1SMN1; SMN2L3MBTL1HTT
SCHEMBL31539439 0.87 MAPT (0.59) MAPTMAPK1SMN1; SMN2L3MBTL1KDM4E
SCHEMBL29852474 0.85 MAPT (0.47) MAPTMAPK1SMN1; SMN2L3MBTL1KDM4E
SCHEMBL12179887 0.83 MAPT (0.56) MAPTMAPK1SMN1; SMN2L3MBTL1KDM4E
SCHEMBL6344652 0.83 MAPT (0.54) MAPTMAPK1SMN1; SMN2KDM4EHTT
SCHEMBL5774784 0.82 MAPT (0.56) MAPTMAPK1SMN1; SMN2L3MBTL1HTT
SCHEMBL7010780 0.81 MAPT (0.53) MAPTMAPK1SMN1; SMN2L3MBTL1KDM4E
SCHEMBL2588689 0.81 TSHR (0.51) MAPTMAPK1SMN1; SMN2L3MBTL1KDM4E
SCHEMBL932150 0.80 MAPT (0.58) MAPTMAPK1SMN1; SMN2L3MBTL1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12570625-B2 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof NOVARTIS AG (CH) 2026-03-10 US disclosed
EP-4126832-B1 MODULATORS OF HEMOGLOBIN GLOBAL BLOOD THERAPEUTICS INC (US) 2026-01-07 EP disclosed
WO-2025085848-A1 ANTIBACTERIAL COMPOUNDS ARREPATH, INC. (US) 2025-04-24 WO disclosed
WO-2025054132-A1 ANTIBACTERIAL COMPOUNDS ARREPATH, INC. (US) 2025-03-13 WO disclosed
CN-112261970-B 3- (5-Hydroxy-1-oxo-isoindolin-2-yl) piperidine-2, 6-dione derivatives and their use in the treatment of IKAROS family zinc finger 2 (IKZF 2) dependent diseases 诺华股份有限公司 2025-02-07 CN disclosed
CN-119241499-A 3- (5-Hydroxy-1-oxo-isoindolin-2-yl) piperidine-2, 6-dione derivatives and uses thereof 诺华股份有限公司 2025-01-03 CN disclosed
EP-4306111-A2 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF Novartis AG (CH) 2024-01-17 EP disclosed
EP-3820573-B1 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF IKAROS FAMILY ZINC FINGER 2 (IKZF2)-DEPENDENT DISEASES NOVARTIS AG (CH) 2023-08-09 EP disclosed
US-20230192611-A1 MODULATORS OF HEMOGLOBIN GLOBAL BLOOD THERAPEUTICS, INC. 2023-06-22 US disclosed
US-20230192611-A1 MODULATORS OF HEMOGLOBIN GLOBAL BLOOD THERAPEUTICS, INC. 2023-06-22 US disclosed
WO-2011134971-A1 7-(1H-PYRAZOL-4-YL)-1,6-NAPHTHYRIDINE COMPOUNDS AS SYK INHIBITORS GLAXO GROUP LIMITED (GB) 2011-11-03 WO disclosed
WO-2011134971-A1 7-(1H-PYRAZOL-4-YL)-1,6-NAPHTHYRIDINE COMPOUNDS AS SYK INHIBITORS GLAXO GROUP LIMITED (GB) 2011-11-03 WO disclosed
US-20100261706-A1 SUBSTITUTED TETRACYCLIC 1H-INDENO [1,2-B]PYRIDINE-2(5H)-ONE ANALOGS THEREOF AND USES THEREOF INOTEK PHARMACEUTICALS CORPORATION (US) 2010-10-14 US disclosed
US-20100261706-A1 SUBSTITUTED TETRACYCLIC 1H-INDENO [1,2-B]PYRIDINE-2(5H)-ONE ANALOGS THEREOF AND USES THEREOF INOTEK PHARMACEUTICALS CORPORATION (US) 2010-10-14 US disclosed
WO-2010077663-A2 SUBSTITUTED TETRACYCLIC 1H-INDENO (1,2-B) PYRIDINE-2 (5H)-ONE ANALOGS THEREOF AND USES THEREOF INOTEK PHARMACEUTICALS CORPORATION (US) 2010-07-08 WO disclosed
EP-1652839-A2 Drug efflux pump inhibitor DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-05-03 EP disclosed
EP-1227084-B1 DRUG DISCHARGE PUMP INHIBITORS TRINE PHARMACEUTICALS INC (US) 2005-12-14 EP disclosed
EP-1227084-A1 DRUG DISCHARGE PUMP INHIBITORS Microcide Pharmaceuticals, Inc. (US) 2002-07-31 EP disclosed
EP-0299663-A2 Antihistaminic aromatic tetrahydroazepinones (and thiones) A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) (US) 1989-01-18 EP disclosed
US-4746657-A ANTIHISTAMINES A. H. ROBINS COMPANY, INCORPORATED (US) 1988-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12570625-B2 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof IKZF1, IKZF2, BCL6 MAPT 3114/4885MAPK1 2820/4885SMN1; SMN2 1967/4885
US-20100261706-A1 SUBSTITUTED TETRACYCLIC 1H-INDENO [1,2-B]PYRIDINE-2(5H)-ONE ANALOGS THEREOF AND USES THEREOF TNNI3, TNNT2, ALDH1A2 MAPT 555/4885MAPK1 877/4885SMN1; SMN2 9/4885
US-20230192611-A1 MODULATORS OF HEMOGLOBIN HBG1, HBG2, HBB MAPT 4227/4885MAPK1 2739/4885SMN1; SMN2 2162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.